- Home
- STR vs SDGR Comparison
STR vs SDGR Comparison
Compare STR & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- SDGR
- Stock Information
- Founded
- STR 2016
- SDGR 1990
- Country
- STR United States
- SDGR United States
- Employees
- STR N/A
- SDGR N/A
- Industry
- STR Oil & Gas Production
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- STR Energy
- SDGR Health Care
- Exchange
- STR Nasdaq
- SDGR Nasdaq
- Market Cap
- STR 1.6B
- SDGR 1.8B
- IPO Year
- STR N/A
- SDGR 2020
- Fundamental
- Price
- STR $20.22
- SDGR $19.96
- Analyst Decision
- STR Buy
- SDGR Buy
- Analyst Count
- STR 5
- SDGR 7
- Target Price
- STR $28.25
- SDGR $32.29
- AVG Volume (30 Days)
- STR 810.3K
- SDGR 891.3K
- Earning Date
- STR 05-07-2025
- SDGR 04-30-2025
- Dividend Yield
- STR 6.93%
- SDGR N/A
- EPS Growth
- STR N/A
- SDGR N/A
- EPS
- STR 0.49
- SDGR N/A
- Revenue
- STR $624,414,000.00
- SDGR $207,539,000.00
- Revenue This Year
- STR N/A
- SDGR $28.69
- Revenue Next Year
- STR $3.12
- SDGR $14.95
- P/E Ratio
- STR $41.22
- SDGR N/A
- Revenue Growth
- STR 5.23
- SDGR N/A
- 52 Week Low
- STR $18.40
- SDGR $16.67
- 52 Week High
- STR $25.95
- SDGR $29.15
- Technical
- Relative Strength Index (RSI)
- STR 52.65
- SDGR 39.05
- Support Level
- STR $20.12
- SDGR $21.34
- Resistance Level
- STR $21.09
- SDGR $22.85
- Average True Range (ATR)
- STR 0.51
- SDGR 1.14
- MACD
- STR 0.09
- SDGR -0.21
- Stochastic Oscillator
- STR 63.14
- SDGR 5.06
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.